BAY987518
PreclinicalSmall molecule
BayerBAY987518 is one of 17 small molecule programs targeting Female. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Female
#DrugCompanyPhaseTrials
1Activella
Eli LillyApproved
Dostarlimab
IncytePhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Versed
CConrado Roberto Hoffmann Filho
Phase 1
Faslodex
FFresenius Kabi USA, LLC
Phase 1
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
MK-8527
Merck & Co.Phase 1
Telpegfilgrastim
XXiamen Amoytop Biotech Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAY987518. EMBL-EBI & Wellcome Sanger Institute.
- [4]